Takeda Drops Some Infringement Claims In Dexilant Suit

Law360, New York (November 16, 2012, 7:27 PM EST) -- Takeda Pharmaceutical Co. Ltd. has determined that a generic rival's pursuit of a competing version of the Dexilant acid reflux treatment does not infringe a handful of its patents, according to a California federal court's Friday filing entering judgment for the generic drugmaker for four of Takeda's six asserted patents.

U.S. District Judge Joseph C. Spero signed off on a consent decree partially letting off the hook TWi Pharmaceuticals Inc., which Takeda has alleged is attempting to co-opt its patent holdings in its attempt to market...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.